Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Leases: 2021-2025

Historic Current Leases for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to $2.3 million.

  • Janux Therapeutics' Current Leases rose 34.99% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 34.99%. This contributed to the annual value of $1.7 million for FY2024, which is 15.29% up from last year.
  • Per Janux Therapeutics' latest filing, its Current Leases stood at $2.3 million for Q3 2025, which was up 21.73% from $1.9 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Current Leases high stood at $2.3 million for Q3 2025, and its period low was $88,000 during Q2 2022.
  • Over the past 3 years, Janux Therapeutics' median Current Leases value was $1.6 million (recorded in 2024), while the average stood at $1.7 million.
  • Data for Janux Therapeutics' Current Leases shows a peak YoY spiked of 1,500.00% (in 2023) over the last 5 years.
  • Over the past 5 years, Janux Therapeutics' Current Leases (Quarterly) stood at $194,000 in 2021, then surged by 293.30% to $763,000 in 2022, then surged by 98.82% to $1.5 million in 2023, then climbed by 15.29% to $1.7 million in 2024, then skyrocketed by 34.99% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $1.9 million for Q2 2025, and $1.8 million during Q1 2025.